FDA Approves Zilurgisertib, an Oral ALK2 Inhibitor, for FOP
FDA Approves Zilurgisertib, an Oral ALK2 Inhibitor, for FOP Pharmacy Times
September 2026
Roundup: FDA Approves Lilly’s Olumiant, AbbVie’s Juvmo, Mirum & Incyte’s Atebrioz
Roundup: FDA Approves Lilly’s Olumiant, AbbVie’s Juvmo, Mirum & Incyte’s Atebrioz Pharmaceutical Executive
FDA Approves AbbVie’s Juvmo for Parkinson Disease
FDA Approves AbbVie's Juvmo for Parkinson Disease Drug Topics
FDA Approves Tavapadon for the Treatment of Parkinson Disease
FDA Approves Tavapadon for the Treatment of Parkinson Disease NeurologyLive
Q&A: Cutlip on the SELUTION SLR DEB’s FDA Approval for Coronary In-Stent Restenosis
Q&A: Cutlip on the SELUTION SLR DEB’s FDA Approval for Coronary In-Stent Restenosis HCPLive